Boland et al (2004) found that there was no significant difference in COX-2 expression, comparing normal breast tissue from reduction mammoplasty and normal breast tissue surrounding ductal carcinoma in situ, and also no difference in COX-2 expression between ductal carcinoma in situ and invasive breast cancer. This evidence concerns the gene PTGS2 and ductal breast carcinoma in situ.